| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Jean-Christophe Marine | Q6169071 |
| Sarah Francoz | Q59999588 | ||
| P2093 | author name string | G Lozano | |
| F Toledo | |||
| M Maetens | |||
| G Wahl | |||
| P2860 | cites work | ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor | Q24306428 |
| Mdm2 promotes the rapid degradation of p53 | Q24322597 | ||
| Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 | Q24328775 | ||
| In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
| Regulation of p53 stability by Mdm2 | Q27860744 | ||
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase | Q28139082 | ||
| The ubiquitin ligase COP1 is a critical negative regulator of p53 | Q28258057 | ||
| Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity | Q28270986 | ||
| Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation | Q28609772 | ||
| Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 | Q29614430 | ||
| Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 | Q29617850 | ||
| Polyubiquitination of p53 by a ubiquitin ligase activity of p300. | Q34190044 | ||
| Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. | Q34283106 | ||
| The MDM2 gene amplification database | Q34672224 | ||
| Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation | Q34761203 | ||
| The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. | Q35944646 | ||
| HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. | Q36347917 | ||
| Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells | Q40410781 | ||
| A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans | Q40490424 | ||
| Yin Yang 1 is a negative regulator of p53. | Q40542917 | ||
| Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development. | Q52043972 | ||
| Conditional allele of mdm2 which encodes a p53 inhibitor | Q77668195 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 927-934 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | Cell Death & Differentiation | Q2943974 |
| P1476 | title | Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 | |
| P478 | volume | 13 |
| Q64063524 | A Single Conserved Amino Acid Residue as a Critical Context-Specific Determinant of the Differential Ability of Mdm2 and MdmX RING Domains to Dimerize |
| Q37249372 | A complex barcode underlies the heterogeneous response of p53 to stress |
| Q37350394 | A genetic variant of Aurora kinase A promotes genomic instability leading to highly malignant skin tumors |
| Q90075355 | A genetic variant within MDM4 3'UTR miRNA binding site is associated with HPV16-positive tumors and survival of oropharyngeal cancer |
| Q37631219 | A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. |
| Q37446442 | A transcription co-factor integrates cell adhesion and motility with the p53 response. |
| Q41779296 | Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells |
| Q27670558 | Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization |
| Q37238851 | Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. |
| Q39664441 | An Analysis of an Interactome for Apoptosis Factor, Ei24/PIG8, Using the Inducible Expression System and Shotgun Proteomics |
| Q24328822 | An essential function of the extreme C-terminus of MDM2 can be provided by MDMX |
| Q34047836 | An invertebrate mdm homolog interacts with p53 and is differentially expressed together with p53 and ras in neoplastic Mytilus trossulus haemocytes |
| Q34390990 | Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. |
| Q36609221 | Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties |
| Q37251881 | Apoptosis gene profiling reveals spatio-temporal regulated expression of the p53/Mdm2 pathway during lens development |
| Q39798807 | CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability |
| Q37536673 | Cellular stress response pathway system as a sentinel ensemble in toxicological screening |
| Q39112125 | Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry |
| Q39960469 | Conserved sequences in the final intron of MDM2 are essential for the regulation of alternative splicing of MDM2 in response to stress. |
| Q37293253 | Control of p53 multimerization by Ubc13 is JNK-regulated |
| Q27933220 | Coordinate control of gene expression noise and interchromosomal interactions in a MAP kinase pathway |
| Q34761024 | Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. |
| Q41888157 | Correlation between oncogenic mutations and parameter sensitivity of the apoptosis pathway model |
| Q42038123 | Decision making of the p53 network: death by integration |
| Q35949604 | Developing genetically engineered mouse models to study tumor suppression |
| Q35071233 | Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. |
| Q26784027 | Direct and Propagated Effects of Small Molecules on Protein-Protein Interaction Networks |
| Q33576843 | Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity |
| Q35859991 | Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection |
| Q93271546 | Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway |
| Q84282108 | Dyskeratosis congenita |
| Q91750497 | Dysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in Cancer Cells |
| Q64971662 | Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor neuron death in spinal muscular atrophy. |
| Q33593066 | Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations |
| Q34360157 | Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice |
| Q37603053 | Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis. |
| Q96954750 | Expression of ncRNAs on the DLK1-DIO3 Locus Is Associated With Basal and Mesenchymal Phenotype in Breast Epithelial Progenitor Cells |
| Q37291405 | Functional characterization of p53 pathway components in the ancient metazoan Trichoplax adhaerens |
| Q35779746 | Genetic Variations in the TP53 Pathway in Native Americans Strongly Suggest Adaptation to the High Altitudes of the Andes. |
| Q34504939 | Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer |
| Q92003310 | Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance |
| Q37352957 | Guardian of corpulence: a hypothesis on p53 signaling in the fat cell |
| Q43208346 | Guilty as CHARGED: p53's expanding role in disease |
| Q39753901 | HDM4 is overexpressed in mantle cell lymphoma and its inhibition induces p21 expression and apoptosis |
| Q38790183 | Huntington Disease as a Neurodevelopmental Disorder and Early Signs of the Disease in Stem Cells. |
| Q24298359 | Hypoxia downregulates p53 but induces apoptosis and enhances expression of BAD in cultures of human syncytiotrophoblasts |
| Q43904364 | Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1α. |
| Q38089906 | Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part I: targeting p53, Mdm2, GADD153/CHOP, GRP78/BiP and heat shock proteins |
| Q34315506 | Inappropriate p53 activation during development induces features of CHARGE syndrome |
| Q37379017 | Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases |
| Q37633894 | Indispensable role of Mdm2/p53 interaction during the embryonic and postnatal inner ear development. |
| Q39336132 | Induction of ASAP (MAP9) contributes to p53 stabilization in response to DNA damage. |
| Q87350483 | Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression |
| Q56976088 | Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53 |
| Q38761904 | Lack of Associations of the MDM4 rs4245739 Polymorphism with Risk of Thyroid Cancer among Iranian-Azeri Patients: a Case-Control Study |
| Q53188377 | MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice. |
| Q36094618 | MDM2 and MDM4: p53 regulators as targets in anticancer therapy |
| Q27853125 | MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. |
| Q41023571 | MDM2-MDM4 molecular interaction investigated by atomic force spectroscopy and surface plasmon resonance |
| Q44435579 | MDM2/MDMX inhibitor peptide: WO2008106507. |
| Q36998027 | MDM2/MDMX: Master negative regulators for p53 and RB |
| Q24337839 | MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway |
| Q37686014 | MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability |
| Q48324948 | MDM4 amplification in a case of de-differentiated liposarcoma and in-silico data supporting an oncogenic event alternative to MDM2 amplification in a subset of cases. |
| Q85072453 | MDM4 overexpression contributes to synoviocyte proliferation in patients with rheumatoid arthritis |
| Q38907224 | MDMX exerts its oncogenic activity via suppression of retinoblastoma protein |
| Q38073178 | MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas |
| Q39912357 | MSL2 promotes Mdm2-independent cytoplasmic localization of p53 |
| Q34503497 | Making sense of ubiquitin ligases that regulate p53 |
| Q37514029 | Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors |
| Q38976292 | Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4. |
| Q41269705 | Mdm2 and Mdm4 loss regulates distinct p53 activities |
| Q42579780 | Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity |
| Q41337111 | Mdm2 promotes genetic instability and transformation independent of p53. |
| Q38983373 | Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma. |
| Q24653892 | Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26 |
| Q37508606 | Mdm2-mediated ubiquitylation: p53 and beyond. |
| Q24336863 | MdmX is a substrate for the deubiquitinating enzyme USP2a |
| Q24316238 | Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase |
| Q35362468 | Mechanisms underlying cancer growth and apoptosis by DEK overexpression in colorectal cancer. |
| Q29615657 | Modes of p53 regulation |
| Q45302322 | Modifications of p53 and the DNA damage response in cells expressing mutant form of the protein huntingtin |
| Q38069375 | Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy |
| Q48121736 | Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx. |
| Q33752174 | Mouse models of p53 functions |
| Q35641901 | Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression |
| Q36070574 | Mutant p53: one name, many proteins |
| Q33320072 | Mutation analysis of the MDM4 gene in German breast cancer patients |
| Q39396732 | Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers |
| Q24337178 | Mutational analysis reveals a dual role of Mdm2 acidic domain in the regulation of p53 stability |
| Q49771217 | Neuroprotective effects of pifithrin-α against traumatic brain injury in the striatum through suppression of neuroinflammation, oxidative stress, autophagy, and apoptosis |
| Q39387810 | New Insights in Thyroid Cancer and p53 Family Proteins. |
| Q34758670 | New insights into p53 activation |
| Q36544705 | Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age. |
| Q38465956 | PATZ1 Is a DNA Damage-Responsive Transcription Factor That Inhibits p53 Function |
| Q51895782 | Pharmacological Rescue of p53 in Cancer Therapy: Widening the Sensitive Tumor Spectrum by Targeting MDMX |
| Q35048287 | Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck |
| Q41287206 | Protecting the genome from mdm2 and mdmx |
| Q35927931 | Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation |
| Q92358617 | Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells |
| Q29615658 | Regulating the p53 pathway: in vitro hypotheses, in vivo veritas |
| Q24294849 | Regulation of MDM4 (MDMX) function by p76(MDM2): a new facet in the control of p53 activity |
| Q39322285 | Regulation of Metabolic Activity by p53. |
| Q92796910 | Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma |
| Q36960990 | Regulation of hematopoietic stem cell fate by the ubiquitin proteasome system |
| Q42825893 | Regulation of p53 in embryonic stem cells |
| Q37992789 | Regulation of p53: a collaboration between Mdm2 and Mdmx |
| Q37801346 | Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. |
| Q80629211 | Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas |
| Q39205536 | Reviving the guardian of the genome: Small molecule activators of p53. |
| Q24321357 | Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain |
| Q35098801 | Roles of HAUSP-mediated p53 regulation in central nervous system development |
| Q84908928 | S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia |
| Q28572542 | SCYL1BP1 modulates neurite outgrowth and regeneration by regulating the Mdm2/p53 pathway |
| Q39521848 | SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. |
| Q37290519 | Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy. |
| Q27027835 | Small molecule compounds targeting the p53 pathway: are we finally making progress? |
| Q37806669 | Small-Molecule Inhibitors of the p53-MDM2 Interaction |
| Q38016673 | Spotlight on the role of COP1 in tumorigenesis |
| Q35140857 | Stochastic modeling and simulation of the p53-MDM2/MDMX loop |
| Q34575687 | Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2. |
| Q42256579 | Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study |
| Q47121747 | Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids |
| Q36777367 | Structure-function-rescue: the diverse nature of common p53 cancer mutants |
| Q28594772 | Synergistic regulation of p53 by Mdm2 and Mdm4 is critical in cardiac endocardial cushion morphogenesis during heart development |
| Q52628104 | TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. |
| Q34626707 | Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy |
| Q55137359 | Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity. |
| Q45951863 | The CXXC finger 5 protein is required for DNA damage-induced p53 activation. |
| Q28071415 | The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target |
| Q37424099 | The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer |
| Q34460686 | The MDM2 gene family |
| Q41287020 | The Many Faces of MDM2 Binding Partners |
| Q34030117 | The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor |
| Q55517350 | The Roles of MDM2 and MDMX in Cancer. |
| Q99708992 | The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing |
| Q37426771 | The Zn-finger domain of MdmX suppresses cancer progression by promoting genome stability in p53-mutant cells |
| Q36189459 | The alternative translated MDMX(p60) isoform regulates MDM2 activity. |
| Q35122947 | The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo |
| Q34020353 | The p53 orchestra: Mdm2 and Mdmx set the tone |
| Q43118033 | The p53--Mdm2--HAUSP complex is involved in p53 stabilization by HAUSP. |
| Q37185622 | The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity |
| Q33685413 | The regulation of the p53-mediated stress response by MDM2 and MDM4. |
| Q37762069 | The tumor suppressor p53: from structures to drug discovery |
| Q33758339 | Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors. |
| Q34121104 | Tissue-specific and age-dependent effects of global Mdm2 loss |
| Q26992094 | Tumor suppression in skin and other tissues via cross-talk between vitamin D- and p53-signaling |
| Q42019037 | Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish |
| Q37591937 | Tumour suppression by p53: a role for the DNA damage response? |
| Q24295055 | Turning the RING domain protein MdmX into an active ubiquitin-protein ligase |
| Q36946774 | Ubiquitin ligases in cancer: ushers for degradation |
| Q39032658 | Ubiquitin-specific protease 2a stabilizes MDM4 and facilitates the p53-mediated intrinsic apoptotic pathway in glioblastoma |
| Q64100741 | Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases |
| Q42058130 | Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo |
| Q42466219 | Wild-type p53 inhibits pro-invasive properties of TGF-β3 in breast cancer, in part through regulation of EPHB2, a new TGF-β target gene |
| Q55471290 | Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics. |
| Q54415844 | [Moderation in all things: p53 deregulation, cancer and telomere syndromes]. |
| Q39310656 | c-Abl phosphorylates Hdmx and regulates its interaction with p53. |
| Q40466065 | miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. |
| Q42412951 | microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma. |
| Q40363516 | p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis |
| Q36387615 | p53 Regulation Goes Live-Mdm2 and MdmX Co-Star: Lessons Learned from Mouse Modeling |
| Q57498203 | p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy |
| Q37602510 | p53 and E2f: partners in life and death |
| Q34029735 | p53 at a glance |
| Q29619939 | p53 in health and disease |
| Q33758261 | p53 is positively regulated by miR-542-3p |
| Q30275107 | p53 pathway is involved in cell competition during mouse embryogenesis |
| Q37376012 | p53 polymorphisms: cancer implications |
| Q37882073 | p53 regulation by ubiquitin |
| Q35103179 | p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome |
| Q54941377 | p53-Autophagy-Metastasis Link. |
| Q37727778 | p53-family proteins and their regulators: hubs and spokes in tumor suppression |
| Q38247164 | p53-independent effects of Mdm2. |
| Q33857597 | p53-mediated hematopoietic stem and progenitor cell competition. |
| Q37865050 | p53-targeted cancer pharmacotherapy: move towards small molecule compounds |
Search more.